Breaking News Instant updates and real-time market news.

MRUS

Merus

$20.22

6.07 (42.90%)

, INCY

Incyte

$99.76

-2.45 (-2.40%)

05:32
12/22/16
12/22
05:32
12/22/16
05:32

Merus upgraded to Buy from Neutral at Citi

Citi analyst Yigal Nochomovitz upgraded Merus (MRUS) to Buy saying the Incyte (INCY) collaboration deal has "very favorable" terms. The deal with a "high-profile" company coupled with a $200M upfront payment "should meaningfully increase Street visibility," Nochomovitz tells investors in a research note. He raised his price target for Merus shares to $26 from $19. The stock closed yesterday up 43% to $20.22.

MRUS

Merus

$20.22

6.07 (42.90%)

INCY

Incyte

$99.76

-2.45 (-2.40%)

  • 09

    Jan

MRUS Merus
$20.22

6.07 (42.90%)

06/13/16
06/13/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Brookfield Renewable (BEP) coverage resumed with an Outperform at BMO Capital. 2. Diamond Offshore (DO) reinstated with a Buy at BofA/Merrill. 3. Merus (MRUS) initiated with a Buy at Citi, a Buy at Guggenheim, and an Outperform at Wedbush. 4. Helmerich & Payne (HP) initiated with a Buy at BofA/Merrill. 5. Dentsply Sirona (XRAY) initiated with an Overweight at Piper Jaffray. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/07/16
SBSH
11/07/16
DOWNGRADE
Target $19
SBSH
Neutral
Merus downgraded to Neutral from Buy at Citi
Citi analyst Yigal Nochomovitz downgraded Merus to Neutral citing valuation with the stock up 100% in the last two months. The analyst sees a less favorable risk/reward into the year-end data for lead breast cancer drug MCLA-128. He raised his price target for the shares to $19 from $14.
12/21/16
WEDB
12/21/16
NO CHANGE
Target $32
WEDB
Outperform
Merus price target rasied to $32 from $16 at Wedbush
12/21/16
JEFF
12/21/16
NO CHANGE
Target $29
JEFF
Buy
Jefferies ups Merus target to $29 after Incyte collaboration
Jefferies analyst Brian Abrahams views today's announced bispecific collaboration between Merus (MRUS) and Incyte (INCY) as a win for Merus. The deal provides "capital flexibility and strong validation" of the company's platform, while enabling maintenance of full rights to its clinical programs, Abrahams tells investors in a research note. He raised his price target for Merus shares to $29 from $21 and keeps a Buy rating on the name. The stock is up 45%, or $6.30, to $20.45 in midday trading.
INCY Incyte
$99.76

-2.45 (-2.40%)

11/18/16
RHCO
11/18/16
NO CHANGE
RHCO
Incyte has several positive catalysts, says SunTrust
SunTrust analyst PEter Lawson says he expects Incyte's baricitinib, which he calls a key profitability driver for the company, to be approved by the FDA next quarter. He also expects the company to benefit from positive data on its epacadostat and IOs in solid tumor settings. The analyst keeps a Buy rating on the shares.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.
12/05/16
RBCM
12/05/16
NO CHANGE
RBCM
Incyte data positive, says RBC Capital
RBC Capital analyst Simos Simeonidis believes that data for Incyte's INCB39110 in GvHD was "promising." The analyst notes that patients who received INCB39110 as a first-line treatment had an 83.3% overall response rate, while the drug was well-tolerated by all patients. He keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

BAH

Booz Allen

$37.17

0.15 (0.41%)

06:48
11/21/17
11/21
06:48
11/21/17
06:48
Initiation
Booz Allen initiated  »

Booz Allen resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 14

    Dec

EWZ

MSCI Brazil Index

$40.19

0.36 (0.90%)

06:47
11/21/17
11/21
06:47
11/21/17
06:47
Technical Analysis
MSCI Brazil Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$78.90

-0.59 (-0.74%)

06:47
11/21/17
11/21
06:47
11/21/17
06:47
Earnings
Medtronic sees FY18 adjusted EPS growth 9%-10%, consensus $4.68 »

Sees FY18 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

GHM

Graham

$19.21

0.35 (1.86%)

06:47
11/21/17
11/21
06:47
11/21/17
06:47
Conference/Events
Graham management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

EFA

iShares MSCI EAFE Index Fund

$69.06

0.15 (0.22%)

06:47
11/21/17
11/21
06:47
11/21/17
06:47
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARDX

Ardelyx

$5.60

-0.1 (-1.75%)

06:46
11/21/17
11/21
06:46
11/21/17
06:46
Hot Stocks
Ardelyx announces updated development path for cardiorenal pipeline »

Ardelyx provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNK

SPDR Barclays High Yield Bond

$36.81

0.02 (0.05%)

06:46
11/21/17
11/21
06:46
11/21/17
06:46
Technical Analysis
SPDR Barclays High Yield Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJB

ProShares Short High Yield

$23.28

0.0328 (0.14%)

06:46
11/21/17
11/21
06:46
11/21/17
06:46
Technical Analysis
ProShares Short High Yield: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$78.90

-0.59 (-0.74%)

06:46
11/21/17
11/21
06:46
11/21/17
06:46
Earnings
Medtronic reports Q2 adjusted EPS $1.07, consensus 98c »

Reports Q2 revenue $7.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

BURL

Burlington Stores

$106.55

1.82 (1.74%)

06:45
11/21/17
11/21
06:45
11/21/17
06:45
Earnings
Burlington Stores reports Q3 adjusted EPS 70c, consensus 65c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

HYG

iShares iBoxx $ High Yield Corporate Bond

$87.49

0.02 (0.02%)

06:45
11/21/17
11/21
06:45
11/21/17
06:45
Technical Analysis
iShares iBoxx $ High Yield Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQD

iShares iBoxx $ Investment Grade Corporate Bond

06:45
11/21/17
11/21
06:45
11/21/17
06:45
Technical Analysis
iShares iBoxx $ Investment Grade Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTU

Intuit

$157.78

1.23 (0.79%)

06:44
11/21/17
11/21
06:44
11/21/17
06:44
Recommendations
Intuit analyst commentary  »

Intuit price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLT

iShares 20+ Year Treasury Bond Fund

$126.34

-0.05 (-0.04%)

06:44
11/21/17
11/21
06:44
11/21/17
06:44
Technical Analysis
iShares 20+ Year Treasury Bond Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRPT

Freshpet

$18.15

0.05 (0.28%)

06:44
11/21/17
11/21
06:44
11/21/17
06:44
Conference/Events
Freshpet management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

KIRK

Kirkland's

$12.82

0.29 (2.31%)

06:43
11/21/17
11/21
06:43
11/21/17
06:43
Earnings
Kirkland's sees FY17 EPS 50c-60c, consensus 60c »

Sees FY17 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

DY

Dycom

$98.22

8.18 (9.08%)

06:43
11/21/17
11/21
06:43
11/21/17
06:43
Recommendations
Dycom analyst commentary  »

Dycom price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 28

    Nov

JEC

Jacobs Engineering

$59.34

0.71 (1.21%)

06:43
11/21/17
11/21
06:43
11/21/17
06:43
Hot Stocks
Breaking Hot Stocks news story on Jacobs Engineering »

Jacobs Engineering says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

JEC

Jacobs Engineering

$59.34

0.71 (1.21%)

06:42
11/21/17
11/21
06:42
11/21/17
06:42
Earnings
Breaking Earnings news story on Jacobs Engineering »

Jacobs Engineering sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

FSCT

ForeScout

$26.94

1.39 (5.44%)

06:42
11/21/17
11/21
06:42
11/21/17
06:42
Initiation
ForeScout initiated  »

ForeScout initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SLV

iShares Silver Trust

$15.98

-0.33 (-2.02%)

06:42
11/21/17
11/21
06:42
11/21/17
06:42
Technical Analysis
iShares Silver Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USLV

VelocityShares 3x Long Silver ETN

$11.72

-0.84 (-6.69%)

06:42
11/21/17
11/21
06:42
11/21/17
06:42
Technical Analysis
VelocityShares 3x Long Silver ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$59.34

0.71 (1.21%)

06:41
11/21/17
11/21
06:41
11/21/17
06:41
Hot Stocks
Jacobs Engineering reports backlog of $19.8B at year end »

Up $1.2B vs. prior…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

PLNT

Planet Fitness

$30.15

0.07 (0.23%)

06:41
11/21/17
11/21
06:41
11/21/17
06:41
Initiation
Planet Fitness initiated  »

Planet Fitness initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$59.34

0.71 (1.21%)

06:40
11/21/17
11/21
06:40
11/21/17
06:40
Earnings
Jacobs Engineering reports Q4 adjusted EPS 98c, consensus 82c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.